Tag:
Bausch & Lomb
Latest Headlines
Latest Headlines
ISTA's hard-to-get stance yields $500M Bausch & Lomb bid
After resisting a bidfrom Valeant, ISTA went to Bausch & Lomb for 40% more.
Bausch & Lomb snags experimental eye treatments in $500M ISTA buyout
Bausch & Lomb's willingness to shell out $500 million has a lot to do with ISTA's pipeline of experimental therapies.
NicOx spikes on successful glaucoma drug study
Shares of France's NicOx spiked on the news that its experimental glaucoma drug licensed to Bausch & Lomb proved positive in a mid-stage study. According to their release two of the four...
Bausch + Lomb eyes pharma ops expansion
You might know it for its contact lenses, but Bausch + Lomb wants you to know it for its pharma offerings, too. Calling pharma his company's "hidden gem," B+L CEO Brent Saunders told PharmaTimes that
Bausch + Lomb makes exec moves
Bausch + Lomb has named Sheila Hopkins as global president of the company's vision care unit, while Peter Valenti III and Steven Robins have assumed new roles within the organization. Hopkins will
Stability tests prompt Bausch & Lomb ReNu recall
Substandard quality identified in routine testing and reports of sensitivity have prompted to Bausch & Lomb to make a two-part precautionary recall of its ReNu contact lens solution in Europe and
Ex-Schering chiefs join up at Bausch
Everyone was watching to see where ex-Schering-Plough chief Fred Hassan ( photo ) would land after the big Merck merger put him out of a job. Which drugmaker would he end up leading next? Well, we have
NicOx gains new partner on glaucoma program
France's NicOx is pocketing a $10 million upfront from Bausch & Lomb to develop and market its glaucoma eye therapy NCX 116. And it stands to earn another $169.5 million in milestones in the
Hassan joins up with private equity firm
Where do pharma CEOs go when they've said goodbye? Apparently, they join a private equity firm. Former Schering-Plough chief Fred Hassan ( photo ) has enlisted at Warburg Pincus as a senior advisor,
Bausch & Lomb settles 600 lawsuits
Bausch & Lomb has settled over 600 lawsuits over the last year, to the tune of $250 million. The suits are from patients who say they were exposed to the fungal infection Fusarium keratitis while
